查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2009083

药品安全监测市场规模、份额、趋势和预测：服务供应商、产品生命週期、类型、流程、治疗领域、最终用途和地区划分，2026-2034 年

Pharmacovigilance Market Size, Share, Trends and Forecast by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3个工作天内

价格

2025年全球药物安全监测市场规模为92亿美元。展望未来，IMARC集团预测，该市场将在2026年至2034年间以7.10%的复合年增长率成长，到2034年达到170亿美元。目前，北美市场主导地位，市占率达33.7%。推动市场扩张的因素包括：药物复杂性日益增加、全球监管日益严格、人工智慧和巨量资料应用日益广泛、多重用药和药物滥用导致的副作用增多，以及製药公司越来越多地将临床和上市后安全管理外包。

药物安全检测市场的发展主要受以下因素驱动：不利事件（ADR）发生率的上升、上市后药物监测需求的成长以及日益严格的全球监管要求。此外，人工智慧（AI）和巨量资料分析的日益普及正在增强讯号检测和药物安全性评估能力，提高效率并促进市场成长。例如，欧洲药品管理局（EMA）于2024年发布了用于药物警戒中人工智慧应用的工具和指南，表明其致力于利用技术改进药物安全监测。此外，製药和生物技术行业的成长推动了药物研发过程中对全面安全监测的需求，进一步促进了市场扩张。慢性病的激增和新药的上市也增加了对健全的药物安全检测系统的需求，从而推动了市场发展。最后，将药物安全检测业务外包给专业公司也透过降低营运成本并在确保合规性的同时推动了市场成长。

美国药物安全检测市场主要受该国庞大的製药产业驱动，该产业进行大量临床试验，需要进行全面的安全监测。生物相似药和个人化医疗的兴起增加了药物安全评估的复杂性，进一步推动了市场需求。同时，政府为促进药物安全监测而采取的倡议，例如美国食品药物管理局（FDA）的「倡议计画」（ Sentinel Initiative），也在推动市场成长。随着以患者为中心的医疗模式日益普及，收集真实世界数据进行安全评估变得愈发重要，从而提升了药物警戒的市场份额。此外，监管机构与製药公司之间的合作正在加强合规和监测体系，为市场成长提供支援。同时，远距远端医疗和数位健康工具的快速普及也促进了市场成长，因为它们能够实现不利事件（ADR）的远距报告和监测。

药物警戒市场的发展趋势：

技术进步正在改变药物安全检测运作。

药物安全检测市场前景凸显了自动化和智慧主导的工作流程在重塑产业格局中发挥的重要作用。人工智慧 (AI)、机器学习 (ML)、自然语言处理 (NLP) 和巨量资料分析等技术正在将传统的药物安全检测模式转变为敏捷、数据丰富的生态系统。这些工具透过快速、大规模地处理大量资料集，增强了核心功能，尤其是在不良反应监测、讯号检测和监管报告方面。近期市场研究表明，全球机器学习 (ML) 市场规模将在 2024 年达到 310 亿美元，而药物警戒将成为成长最快的应用领域之一。极具影响力的合作正在树立新的标准。例如，赛诺菲和德勤的 ConvergeHEALTH Safety 平台利用人工智慧简化了病例登记流程，而 ArisGlobal 与美国食品药物管理局的 FAERS II 系统集成，则提升了电子安全报告的提交效率。 Saama Technologies 的 ASAP 解决方案利用 FDA 的 Sentinel通用资料模型和 TreeScan调查方法，进一步推进即时风险检测。

政府法规和真实世界数据正在推动市场扩张。

目前药物警戒市场概览清楚地表明，全球监管机构的审查力度正在增加。鑑于新药和复杂疗法的不断涌现，美国FDA、EMA、CDSCO和TGA等监管机构正在透过实施更严格的安全报告要求来加强治疗方法。 Aurobindo Pharma USA召回喹Quinapril和氢氯噻嗪片（原因是亚硝胺污染）的事件凸显了提高检测标准的必要性。此类事件促使製药公司加强内部系统并寻求外部药物警戒合作伙伴。随着对上市后监测的依赖性日益增强，不利事件（ADR）监测的关键作用也日益受到关注，尤其是在药物滥用和多重用药日益增多的背景下。监管机构的期望不仅针对临床试验阶段，也针对能反映患者长期疗效的真实世界使用数据。发表在《药物安全与监管前沿》上的一项研究强调了真实世界数据 (RWE) 在更新临床环境以外的药物风险概况方面的价值。

药品的日益复杂化推动了对药物安全检测服务的需求不断增长。

药物警戒市场的最新趋势表明，製药公司对专业安全监测服务的需求激增。推动这一转变的主要因素之一是新药生产日益复杂，尤其是在生物製药、基因疗法和个人化医疗领域。疾病负担日益恶化（尤其是慢性病和共病），患者往往需要同时服用多种药物，这增加了药物交互作用和意外不良反应的风险。为了应对这种复杂性，药厂正将药物警戒业务外包给专业的服务供应商。这些公司提供可扩展的基础设施、经验丰富的分析师以及获取区域监管资讯的管道。 IQVIA 与 NRx Pharmaceuticals 在医疗资讯和药物警戒方面的策略合作表明，外包已从单纯的成本削减发展到绩效提升。这一趋势也反映了药物警戒市场报告中的另一个关键见解：内部资源往往人手不足。外包使企业能够专注于核心创新，同时在全球市场保持端到端的药物安全监测。

复杂的临床试验和多种药物联合使用正在推动市场发展。

临床试验数量和复杂性的不断增加是药物安全检测市场预期成长的主要驱动因素。近期市场数据显示，2023年将启动超过22,000项新试验，其中许多试验将采用自适应通讯协定、分散式元素和以患者为中心的设计。这些趋势凸显了对能够跨多个地区即时运作的敏捷、主动式安全系统的迫切需求。此外，随着心血管疾病、糖尿病和癌症等慢性疾病的日益增多，患者往往被迫接受多重用药，即多种药物合併使用。这显着增加了安全风险，使得不利事件（ADR）监测比以往任何时候都更重要。而这发展趋势的核心在于技术主导的伙伴关係。 Cognizant与分散式临床试验（DCT）平台领导者Medable的合作，已将简化的安全监测引入试验的每个环节。同样，Viedoc与LINK Medical的伙伴关係旨在透过整合药物安全监测工具，支援协作式功能性试验并提高试验效率。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：全球药品安全监测市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依服务供应商划分

  • 内部
  • 基于合约的外包

第七章 市场区隔：依产品生命週期划分

  • 临床前
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第八章 市场区隔：依类型

  • 自愿报告
  • 加强ADR报告
  • 有针对性的自愿报告
  • 伫列心臟事件记录器
  • 电子健康记录挖掘

第九章 市场区隔：依流程划分

  • 案例资料管理
    • 主要类型
      • 病例记录
      • 案例数据分析
      • 医学审查和报告
  • 讯号检测
    • 主要类型
      • 不利事件记录
      • 不利事件分析
      • 不利事件的审查和报告
  • 风险管理系统
    • 主要类型
      • 风险评估系统
      • 风险缓解系统

第十章 市场区隔：依治疗领域划分

  • 肿瘤学
  • 神经病学
  • 循环系统
  • 呼吸系统
  • 其他的

第十一章 市场区隔：依最终用途划分

  • 製药公司
  • 生技公司
  • 医疗设备製造商
  • 其他的

第十二章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十三章 SWOT 分析

第十四章：价值链分析

第十五章：波特五力分析

第十六章：价格分析

第十七章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Accenture plc
    • ArisGlobal LLC
    • BioClinica Inc.（Cinven Partners LLP）
    • Capgemini
    • Cognizant
    • International Business Machines Corporation
    • ICON plc.
    • IQVIA Inc.
    • ITClinical
    • Parexel International Corporation
    • Wipro Limited
Product Code: SR112026A3609

The global pharmacovigilance market size was valued at USD 9.2 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 17.0 Billion by 2034, exhibiting a CAGR of 7.10% from 2026-2034. North America currently dominates the market, holding a share of 33.7%. The market is expanding due to rising drug complexity, strict global regulations, growing use of AI and big data, increased adverse drug reactions from polypharmacy and substance abuse, and greater outsourcing by pharmaceutical firms to manage clinical and post-marketing safety.

The pharmacovigilance market is driven by the growing prevalence of adverse drug reactions (ADRs), increasing demand for post-market drug monitoring, and stricter regulatory requirements worldwide. In addition, the rising adoption of artificial intelligence (AI) and big data analytics enhances signal detection and drug safety evaluation, improving efficiency and aiding the market growth. For instance, in 2024 European Medicines Agency (EMA) released tools and guidelines for using AI in pharmacovigilance, hereby showing a willingness to use technology to improve drug safety monitoring. Additionally, the growth of the pharmaceutical and biotechnology industries drives the demand for thorough safety monitoring during drug development, further contributing to the market's expansion. Besides this, the surge in chronic diseases and new drug launches boosts the demand for robust pharmacovigilance systems, providing an impetus to the market. Furthermore, outsourcing pharmacovigilance activities to specialized firms reduces operational costs while maintaining compliance, thus catalyzing the market growth.

The United States pharmacovigilance market is strongly driven by the country's extensive pharmaceutical industry, which conducts numerous clinical trials requiring thorough safety monitoring. In line with this, the rise of biosimilars and personalized medicine increases the complexity of drug safety assessments, boosting the market demand. Concurrently, government initiatives promoting drug safety surveillance, such as the Food and Drug Administration's (FDA) Sentinel Initiative, are fostering the market growth. In confluence with this, the growing integration of patient-centric approaches emphasizes real-world data collection for safety evaluations, strengthening the pharmacovigilance market share. Also, collaborations between regulatory bodies and pharmaceutical companies enhance compliance and monitoring systems, supporting the market growth. Apart from this, the rapid adoption of telemedicine and digital health tools fosters remote reporting and monitoring of ADRs, propelling the market forward.

PHARMACOVIGILANCE MARKET TRENDS:

Technological Advancements Transforming Pharmacovigilance Operations

The pharmacovigilance market outlook highlights the role of automation and intelligence-driven workflows in redefining the landscape. Technologies such as AI, machine learning (ML), natural language processing (NLP), and big data analytics are transforming traditional pharmacovigilance models into agile, data-rich ecosystems. These tools are enhancing core functions-especially ADR monitoring, signal detection, and regulatory reporting-by processing massive datasets at speed and scale. According to recent market research, the global ML industry reached USD 31 billion in 2024, with pharmacovigilance emerging as one of its fastest-growing applications. High-impact collaborations are setting new benchmarks: Sanofi and Deloitte's ConvergeHEALTH Safety platform uses AI to streamline case intake, while ArisGlobal's integration with the USFDA's FAERS II system has enhanced electronic safety submissions. Saama Technologies' ASAP solution further advances real-time risk detection, drawing on the FDA's Sentinel Common Data Model and TreeScan methodology.

Government Regulation and Real-World Evidence Reinforce Market Expansion

A clear takeaway from the current pharmacovigilance market overview is the intensification of global regulatory scrutiny. Agencies like the USFDA, EMA, CDSCO, and TGA are increasing their vigilance, issuing strict mandates around safety reporting, especially in light of the rising production of novel drugs and complex therapies. Aurobindo Pharma USA's recall of Quinapril and Hydrochlorothiazide tablets-due to nitrosamine contaminants-highlights how stricter testing standards are becoming non-negotiable. These episodes are driving pharmaceutical firms to reinforce internal systems and seek external pharmacovigilance partners. The growing reliance on post-marketing surveillance has also spotlighted the critical role of ADR monitoring, particularly in an environment of increased drug abuse and polypharmacy. Regulatory expectations are now focused on both trial phases and real-world usage data that captures patient outcomes over time. A study in Frontiers in Drug Safety and Regulation emphasized the value of real-world evidence (RWE) in updating drug risk profiles beyond the clinical setting.

Rising Pharma Demand for Pharmacovigilance Services Amid Drug Complexity

The latest pharmacovigilance market trends point to a surge in demand from pharmaceutical companies for specialized safety monitoring services. One of the core drivers behind this shift is the growing complexity of novel drug production, especially in biologics, gene therapies, and personalized medicine. With disease burdens rising-particularly chronic and comorbid conditions-patients are often prescribed multiple drugs simultaneously, increasing the chances of interactions and unexpected adverse reactions. To manage this complexity, pharma companies are outsourcing pharmacovigilance tasks to expert service providers. These firms offer scalable infrastructure, experienced analysts, and access to regional regulatory intelligence. IQVIA's strategic partnership with NRx Pharmaceuticals for medical information and pharmacovigilance illustrates how outsourcing has evolved from cost-cutting to performance enhancement. This trend also reflects another key insight from the pharmacovigilance market report: internal resources are often overstretched. Outsourcing enables organizations to focus on core innovation while ensuring end-to-end drug safety monitoring is maintained across global markets.

Complex Clinical Trials and Polypharmacy Fuel Market Momentum

The increasing number and complexity of clinical trials are major growth engines for the pharmacovigilance market forecast. According to recent market data, over 22,000 new trials were launched in 2023, with many featuring adaptive protocols, decentralized elements, and patient-centric designs. These trends underscore the need for agile and proactive safety systems that can function in real-time across multiple geographies. Moreover, the rise of chronic diseases-like cardiovascular conditions, diabetes, and cancer-means that patients often undergo polypharmacy, i.e., simultaneous use of multiple therapeutic agents. This adds significant layers of safety risk, making ADR monitoring more vital than ever. Tech-driven partnerships are at the heart of this evolution. Cognizant's collaboration with Medable-a leader in decentralized clinical trial (DCT) platforms-has introduced streamlined safety monitoring at every trial touchpoint. Likewise, Viedoc and LINK Medical's partnership was built to support collaborative feature testing and improve trial productivity through integrated pharmacovigilance tools.

PHARMACOVIGILANCE INDUSTRY SEGMENTATION:

Analysis by Service Provider:

  • In-house
  • Contract Outsourcing

Contract outsourcing is the most popular segment and holds 61.2% market share since it is more affordable and productive in terms of compliance with regulatory requirements and risk monitoring. The pharmacovigilance outsourcing trend has become common with more pharmaceutical and biotechnology companies opting to outsource the processes as a way of avoiding operational costs and focusing on business strengths such as product research and marketing. The increasing stringency of the safety requirements for drugs across the world also increases the need for contract service organizations that have niche competence in the regulation's affairs and other safety assessment techniques. These providers use advanced technologies such as AI and big data analytics to enhance the outcomes of adverse event identification and notification. Also, the increase in the number of clinical trials, new drug launches, and growth in the biosimilars segment supports the growth of this segment. Both contract service providers and pharmaceutical firms are continuously building up their capabilities through more strategic collaborations, making this segment more dominant in the pharmacovigilance market.

Analysis by Product Life Cycle:

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Phase IV or the post-marketing surveillance phase has the biggest market share of 76.5% in the pharmacovigilance market as the monitoring of drug safety after approval is crucial. The dominance of the segment is due to the regulatory requirements for constant safety assessments and risk management procedures. Higher numbers of ADRs observed after approval add to the need for Phase IV to ascertain long-term safety. The pharmaceutical business and increasing number of drugs launches again broaden this segment as firms have to follow safety surveillance standards. Furthermore, new Phase IV activities that combine RWE and big data analytics enable efficient and compliant safety assessments. The ability to outsource Phase IV pharmacovigilance services to specialized service providers that offer cost-effective and compliant post-market surveillance is another factor driving segment growth.

Analysis by Type:

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

The global pharmacovigilance market is led by the spontaneous reporting method with a share of 31.9% due to its high usage in identifying ADRs at a relatively low cost and time. The growth of this segment is due to the compliance standards on healthcare professionals and pharma companies, to report ADRs to central repositories such as the FAERS. This approach to data collection is quicker and means that safety issues can be identified very quickly. Greater public awareness and patient promotion to report ADRs directly also expand the size of this segment. The use of sophisticated technologies like ML and NLP advanced data analysis from spontaneous reports, signals, and risks. With the steady rise in the consumption of drugs all over the world, the need for monitoring the safety of these drugs through spontaneous reporting systems enhances the growth of this segment.

Analysis by Process Flow:

  • Case Data Management
    • Case Logging
    • Case Data Analysis
    • Medical Reviewing and Reporting
  • Signal Detection
    • Adverse Event Logging
    • Adverse Event Analysis
    • Adverse Event Review and Reporting
  • Risk Management System
    • Risk Evaluation System
    • Risk Mitigation System

Signal detection constitutes the largest segment of the pharmacovigilance market with a market share of 38.2% because it plays a central role in detecting and managing safety concerns that may exist about a drug during its development and after launch. The foundation of this process lies in the collection of real-time data from clinical trials, electronic health records (EHRs), and patient records, gathered through adverse event logging. Modern technologies particularly ML algorithms increase the efficiency of adverse event analysis thus enhancing the improvement of drug safety. The increased compliance with regulatory frameworks enhances adverse event review and reporting to meet the required time and quality standards of reporting to the regulatory authorities. Signal detection is anticipated to record strong growth due to the rising uptake of big data analytics as well as the integration of RWE alongside growth in drug development projects and public awareness of drug safety.

Analysis by Therapeutic Area:

  • Oncology
  • Neurology
  • Cardiology
  • Respiratory Systems
  • Others

The pharmacovigilance market is led by oncology as it has the largest market share of 27.8%. Oncology has the highest number of clinical trials and approved drugs as a therapeutic area. The increasing occurrence of cancer all over the world, estimated to be 29,564,943 cases in 2040, fosters the development of oncology drugs and the comprehensiveness of safety measures. Personalized medicine and immunotherapies increase the complexity of adverse event reporting by targeted therapies, and for this reason, necessitate the use of pharmacovigilance processes. The US FDA pressure on the highly secure oncology treatment adds to the market intensity. Also, expensive, and long oncology trials stress the need to have optimum risk management approaches and post-market vigilance to safeguard the patient from any harm while meeting legal compliance requirements. Due to this directed focus on oncology pharmacovigilance, the development of data analytics and AI signal detection innovation is further fueled and market expansion is sustained.

Analysis by End Use:

  • Pharmaceuticals Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Others

The largest segment in the pharmacovigilance market is occupied by pharmaceutical companies with a share of 44.2% because of their significant responsibilities within drug development and safety. They spend a lot of money on pharmacovigilance to meet set regulatory requirements and reduce the potential consequences of ADRs. The increasing numbers of new chemical entities and clinical trials contribute to the escalating demand for sound pharmacovigilance practices. In personal medicine and other biologic products, tracking and risk assessment become difficult; hence, pharmaceutical companies use robust instruments like AI for signal detection. Further, the global engagements between pharmaceutical firms and other regulatory authority organizations improve compliance and data sharing. The continuously rising public concern over drug safety and the shift towards RWE continue to cause pharmaceutical companies to be the most significant drivers of the pharmacovigilance market growth.

Analysis by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America holds the largest share of the pharmacovigilance market at 33.7%, driven by advanced healthcare infrastructure, including the 6,120 hospitals and 916,752 staffed beds in the U.S. along with stringent regulatory frameworks established by the FDA. The region benefits from significant investments in drug safety programs and the widespread adoption of technology for adverse event reporting and data analysis. The rising prevalence of chronic diseases and an aging population are driving the increase in drug consumption, which in turn heightens the demand for effective pharmacovigilance practices. Moreover, the region leads in the integration of AI and big data for signal detection and real-time monitoring, improving efficiency and compliance. Robust collaboration between pharmaceutical companies and research institutions also plays a key role in supporting drug safety initiatives, driving ongoing market growth. The growing focus on patient safety and rising awareness about ADRs solidify North America's leadership in the pharmacovigilance market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES PHARMACOVIGILANCE MARKET ANALYSIS

The United States accounted for a share of 83.40% in the North America pharmacovigilance market in 2025. The US pharmacovigilance market is driven by a combination of stringent regulatory frameworks, technological advancements, and increasing healthcare awareness. The FDA enforces robust pharmacovigilance requirements, fostering the demand for comprehensive adverse event reporting and monitoring systems. With rising concerns over medication safety and side effects, there is a growing need for post-market surveillance, further propelling market growth. According to the US Department of Health and Human Services, an estimated 129 million people in the US suffer from at least one major chronic disease, such as heart disease, cancer, diabetes, obesity, or hypertension, which drives the demand for continuous drug safety monitoring. Technological advancements like AI, ML, and automation are improving drug safety monitoring by increasing both efficiency and accuracy in the detection of adverse events. The integration of EHRs and wearable devices also contributes to real-time safety data collection, enabling faster response to potential risks. Additionally, increasing collaborations between pharmaceutical companies and third-party service providers for pharmacovigilance outsourcing optimize operational costs and ensure compliance with global safety standards. The focus on personalized medicine and the growth of biologics further intensifies the need for robust pharmacovigilance practices in the US market.

EUROPE PHARMACOVIGILANCE MARKET ANALYSIS

The pharmacovigilance market in Europe is highly driven by an effective regulatory framework set down by the EMA and individual country agencies. The uptake of the EU Pharmacovigilance Directive (2010/84/EU) has provided more impetus to the expected safety monitoring and reporting by the pharmaceutical industries. With concern for patient safety, estimations of pharmacovigilance services have gained importance as adverse event reporting and risk management plans are a substantial part of drug development and post-marketing surveillance. The threat level of diseases including cancer, diabetes, and respiratory illnesses amongst others, along with the growing elderly population creates the need for constant safety evaluation of drugs. According to reports, on January 1, 2023, the EU population of 448.8 million, and more than one-fifth of the people are 65 years and above, thus requiring better pharmacovigilance to address the aging population. Furthermore, the application of modern technologies, including big data, AI, and EHRs, as a consequence, contributes to the pharmacovigilance improvement and early identification of ADRs. The European market is also following the overall trend towards outsourcing pharmacovigilance services to specialized contract research organizations (CROs), thus supporting the market growth.

ASIA PACIFIC PHARMACOVIGILANCE MARKET ANALYSIS

The pharmacovigilance market in the Asia-Pacific (APAC) region is expanding rapidly, driven by the region's growing pharmaceutical industry and increasing drug consumption. The prevalence of chronic diseases and the rising need for effective post-market surveillance are key factors fueling this growth. The demand for pharmacovigilance services is particularly prominent due to the increasing focus on drug safety and the need for risk management. As reported by PubMed Central, the prevalence of knee pain among older Asian populations varies significantly, with rates ranging from 11% to 56% in China, 33% in Japan, 38% in Korea, and 61% in Vietnam, underscoring the importance of monitoring treatments in aging populations. Emerging markets like China and India are witnessing significant investments in healthcare infrastructure, improving the collection and analysis of pharmacovigilance data. Moreover, the rising trend of clinical trials in the region further necessitates robust pharmacovigilance systems. Technological advancements, such as EHRs, are enhancing the monitoring of ADRs, further boosting market growth in the region.

LATIN AMERICA PHARMACOVIGILANCE MARKET ANALYSIS

The Latin American pharmacovigilance market is driven by an increasing demand for regulatory compliance and drug safety monitoring, primarily due to the region's expanding pharmaceutical sector and rising healthcare awareness. According to PubMed Central, in Brazil, an estimated 928,000 deaths annually are attributed to chronic diseases, highlighting the need for effective pharmacovigilance systems to manage medication risks in such populations. Key factors contributing to market growth include the implementation of stricter regulatory guidelines by national agencies such as ANVISA in Brazil and COFEPRIS in Mexico. Moreover, the growing adoption of advanced technologies for drug monitoring and the outsourcing of pharmacovigilance services are major factors driving the market.

MIDDLE EAST AND AFRICA PHARMACOVIGILANCE MARKET ANALYSIS

The pharmacovigilance market in the Middle East and Africa (MEA) is influenced by regulatory improvements, increasing healthcare infrastructure, and rising awareness of drug safety. According to PubMed Central, in the UAE, the prevalence of self-reported chronic diseases is 23.0%, with obesity, diabetes, and asthma/allergies being the most common (12.5%, 4.2%, and 3.2%, respectively). This high prevalence of chronic conditions drives the demand for robust pharmacovigilance systems to ensure patient safety. The region's pharmaceutical market is expanding, and with rising healthcare infrastructure and the growth of clinical trials, the need for comprehensive drug safety monitoring continues to rise across MEA.

COMPETITIVE LANDSCAPE:

The pharmacovigilance market is experiencing heightened competition, with leading players concentrating on technological innovations and strategic partnerships to improve their service offerings. There is a growing trend toward leveraging AI and ML for automated adverse event detection and predictive analytics. Companies are expanding their global presence by outsourcing pharmacovigilance services to emerging markets, aiming to reduce operational costs while maintaining high standards. Strategic partnerships with clinical research organizations and healthcare providers are becoming common to streamline data collection and analysis. Additionally, the integration of RWE and patient-reported outcomes into safety assessments is gaining momentum, reflecting the industry's commitment to improving drug safety and regulatory compliance. These activities underline the dynamic evolution of the market landscape.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What is pharmacovigilance?

2. How big is the pharmacovigilance market?

3. What is the expected growth rate of the global pharmacovigilance market during 2026-2034?

4. What are the key factors driving the global pharmacovigilance market?

5. What is the leading segment of the global pharmacovigilance market based on service provider?

6. What is the leading segment of the global pharmacovigilance market based on product life cycle?

7. What is the leading segment of the global pharmacovigilance market based on type?

8. What is the leading segment of the global pharmacovigilance market based on process flow?

9. What is the leading segment of the global pharmacovigilance market based on therapeutic area?

10. What is the leading segment of the global pharmacovigilance market based on end use?

11. What are the key regions in the global pharmacovigilance market?

12. Who are the key players/companies in the global pharmacovigilance market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmacovigilance Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Service Provider

  • 6.1 In-house
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Contract Outsourcing
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Life Cycle

  • 7.1 Pre-clinical
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Phase I
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Phase II
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Phase III
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Phase IV
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Type

  • 8.1 Spontaneous Reporting
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Intensified ADR Reporting
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Targeted Spontaneous Reporting
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cohort Event Monitoring
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 EHR Mining
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Process Flow

  • 9.1 Case Data Management
    • 9.1.1 Market Trends
    • 9.1.2 Major Types
      • 9.1.2.1 Case Logging
      • 9.1.2.2 Case Data Analysis
      • 9.1.2.3 Medical Reviewing and Reporting
    • 9.1.3 Market Forecast
  • 9.2 Signal Detection
    • 9.2.1 Market Trends
    • 9.2.2 Major Types
      • 9.2.2.1 Adverse Event Logging
      • 9.2.2.2 Adverse Event Analysis
      • 9.2.2.3 Adverse Event Review and Reporting
    • 9.2.3 Market Forecast
  • 9.3 Risk Management System
    • 9.3.1 Market Trends
    • 9.3.2 Major Types
      • 9.3.2.1 Risk Evaluation System
      • 9.3.2.2 Risk Mitigation System
    • 9.3.3 Market Forecast

10 Market Breakup by Therapeutic Area

  • 10.1 Oncology
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Neurology
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Cardiology
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Respiratory Systems
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Others
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 Market Breakup by End Use

  • 11.1 Pharmaceuticals Companies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Biotechnology Companies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Medical Device Companies
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Others
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 Accenture plc
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 ArisGlobal LLC
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
    • 17.3.3 BioClinica Inc. (Cinven Partners LLP)
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
      • 17.3.3.3 SWOT Analysis
    • 17.3.4 Capgemini
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio
    • 17.3.5 Cognizant
      • 17.3.5.1 Company Overview
      • 17.3.5.2 Product Portfolio
      • 17.3.5.3 Financials
      • 17.3.5.4 SWOT Analysis
    • 17.3.6 International Business Machines Corporation
      • 17.3.6.1 Company Overview
      • 17.3.6.2 Product Portfolio
      • 17.3.6.3 Financials
      • 17.3.6.4 SWOT Analysis
    • 17.3.7 ICON plc.
      • 17.3.7.1 Company Overview
      • 17.3.7.2 Product Portfolio
      • 17.3.7.3 Financials
      • 17.3.7.4 SWOT Analysis
    • 17.3.8 IQVIA Inc.
      • 17.3.8.1 Company Overview
      • 17.3.8.2 Product Portfolio
      • 17.3.8.3 Financials
      • 17.3.8.4 SWOT Analysis
    • 17.3.9 ITClinical
      • 17.3.9.1 Company Overview
      • 17.3.9.2 Product Portfolio
    • 17.3.10 Parexel International Corporation
      • 17.3.10.1 Company Overview
      • 17.3.10.2 Product Portfolio
      • 17.3.10.3 SWOT Analysis
    • 17.3.11 Wipro Limited
      • 17.3.11.1 Company Overview
      • 17.3.11.2 Product Portfolio
      • 17.3.11.3 Financials
      • 17.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pharmacovigilance Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmacovigilance Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Pharmacovigilance Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Pharmacovigilance Market: Breakup by Service Provider (in %), 2025
  • Figure 5: Global: Pharmacovigilance Market: Breakup by Product Life Cycle (in %), 2025
  • Figure 6: Global: Pharmacovigilance Market: Breakup by Type (in %), 2025
  • Figure 7: Global: Pharmacovigilance Market: Breakup by Process Flow (in %), 2025
  • Figure 8: Global: Pharmacovigilance Market: Breakup by Therapeutic Area (in %), 2025
  • Figure 9: Global: Pharmacovigilance Market: Breakup by End Use (in %), 2025
  • Figure 10: Global: Pharmacovigilance Market: Breakup by Region (in %), 2025
  • Figure 11: Global: Pharmacovigilance (In-house) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Pharmacovigilance (In-house) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Pharmacovigilance (Contract Outsourcing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Pharmacovigilance (Contract Outsourcing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Pharmacovigilance (Pre-clinical) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Pharmacovigilance (Pre-clinical) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Pharmacovigilance (Phase I) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Pharmacovigilance (Phase I) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Pharmacovigilance (Phase II) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Pharmacovigilance (Phase II) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Pharmacovigilance (Phase III) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Pharmacovigilance (Phase III) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Pharmacovigilance (Phase IV) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Pharmacovigilance (Phase IV) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Pharmacovigilance (Spontaneous Reporting) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Pharmacovigilance (Spontaneous Reporting) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Pharmacovigilance (Intensified ADR Reporting) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Pharmacovigilance (Intensified ADR Reporting) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Pharmacovigilance (Targeted Spontaneous Reporting) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Pharmacovigilance (Targeted Spontaneous Reporting) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Pharmacovigilance (Cohort Event Monitoring) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Pharmacovigilance (Cohort Event Monitoring) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Pharmacovigilance (EHR Mining) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Pharmacovigilance (EHR Mining) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Pharmacovigilance (Case Data Management) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Pharmacovigilance (Case Data Management) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Pharmacovigilance (Signal Detection) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Pharmacovigilance (Signal Detection) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Pharmacovigilance (Risk Management System) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Pharmacovigilance (Risk Management System) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Global: Pharmacovigilance (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Global: Pharmacovigilance (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Global: Pharmacovigilance (Neurology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Global: Pharmacovigilance (Neurology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Global: Pharmacovigilance (Cardiology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Global: Pharmacovigilance (Cardiology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Global: Pharmacovigilance (Respiratory Systems) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Global: Pharmacovigilance (Respiratory Systems) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Global: Pharmacovigilance (Other Therapeutic Areas) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Global: Pharmacovigilance (Other Therapeutic Areas) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Global: Pharmacovigilance (Pharmaceuticals Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Global: Pharmacovigilance (Pharmaceuticals Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Global: Pharmacovigilance (Biotechnology Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Global: Pharmacovigilance (Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Global: Pharmacovigilance (Medical Device Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Global: Pharmacovigilance (Medical Device Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Global: Pharmacovigilance (Other End Uses) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Global: Pharmacovigilance (Other End Uses) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: North America: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: North America: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: United States: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: United States: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Canada: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Canada: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Asia-Pacific: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Asia-Pacific: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: China: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: China: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Japan: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Japan: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: India: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: India: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: South Korea: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: South Korea: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Australia: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Australia: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Indonesia: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Indonesia: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Others: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Others: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Europe: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Europe: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Germany: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Germany: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: France: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: France: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: United Kingdom: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 88: United Kingdom: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Italy: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 90: Italy: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 91: Spain: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 92: Spain: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 93: Russia: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 94: Russia: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 95: Others: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 96: Others: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 97: Latin America: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 98: Latin America: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 99: Brazil: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 100: Brazil: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 101: Mexico: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 102: Mexico: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 103: Others: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 104: Others: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 105: Middle East and Africa: Pharmacovigilance Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 106: Middle East and Africa: Pharmacovigilance Market: Breakup by Country (in %), 2025
  • Figure 107: Middle East and Africa: Pharmacovigilance Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 108: Global: Pharmacovigilance Industry: SWOT Analysis
  • Figure 109: Global: Pharmacovigilance Industry: Value Chain Analysis
  • Figure 110: Global: Pharmacovigilance Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmacovigilance Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Pharmacovigilance Market Forecast: Breakup by Service Provider (in Million USD), 2026-2034
  • Table 3: Global: Pharmacovigilance Market Forecast: Breakup by Product Life Cycle (in Million USD), 2026-2034
  • Table 4: Global: Pharmacovigilance Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 5: Global: Pharmacovigilance Market Forecast: Breakup by Process Flow (in Million USD), 2026-2034
  • Table 6: Global: Pharmacovigilance Market Forecast: Breakup by Therapeutic Area (in Million USD), 2026-2034
  • Table 7: Global: Pharmacovigilance Market Forecast: Breakup by End Use (in Million USD), 2026-2034
  • Table 8: Global: Pharmacovigilance Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 9: Global: Pharmacovigilance Market: Competitive Structure
  • Table 10: Global: Pharmacovigilance Market: Key Players